Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
-
* Corresponding author: Haya Ascher-Svanum haya@lilly.com
Cost Effectiveness and Resource Allocation 2009, 7:4 doi:10.1186/1478-7547-7-4
Accesses
- Last 30 days: 140 accesses
- Last 365 days: 1856 accesses
- All time: 6603 accesses